Personalized immunosuppression for kidney transplant recipients using real-world data and AI
Official title: Individualized immunosuppression in organ transplant recipients based on real world evidence and artificial intelligence
Funded at New York University School of Medicine · NIH-11413765 · Data updated 2026-11-12
A kidney transplant grant aims to tailor immunosuppressive therapy to individual patients using real-world health data and artificial intelligence.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 15, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $846,354 |
| NIH project number | 5R01DK144783-02 |
| Project ID | NIH-11413765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Kidney transplant recipients who are on lifelong immunosuppression and have diverse health data available in Epic Cosmos.
✕Less likely to help
Patients not on immunosuppressive therapy or without access to comprehensive electronic health records may not directly benefit.
What this research studies
This project will use large electronic health record data from Epic Cosmos to study how different immunosuppression regimens affect outcomes and adverse drug events in kidney transplant recipients. The team will develop AI-driven approaches to identify which regimens minimize infections, cancer, and cardiovascular risks while preventing rejection. By analyzing detailed, longitudinal data from tens of thousands of patients, doctors hope to move beyond one-size-fits-all treatment and improve long-term graft survival and patient health. The work is designed to translate real-world evidence into personalized care decisions for kidney transplant patients.
Why it matters
Potential benefit: If successful, patients could receive more effective, safer immunosuppression tailored to their risk profile, potentially reducing complications and improving graft longevity.
How similar studies have gone: Prior work shows variability in center protocols; this study adds real-world, granular data to tailor therapy, with potential for impactful improvements.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Bae, Sunjae — New York University School of Medicine
- Study coordinator: Bae, Sunjae
Related research
Other NIH-funded projects on the same topics.
-
Biomarker-guided reduction of immunosuppression after liver transplant
A multicenter trial tests whether using blood biomarkers to guide tapering of immunosuppression in adults with liver transplants can keep people healthy while lowering drug exposure.
-
Biomarkers to tailor liver transplant immunosuppression
A multi-center study using blood biomarkers to guide how immunosuppressive drugs are given to liver transplant patients.
-
Using blood biomarkers to guide immunosuppression after liver transplant
This project uses regular blood biomarker checks to help doctors personalize immunosuppression for people who have had a liver transplant to reduce rejection and protect the kidneys.
-
Optimizing Immunosuppression and EBV-Seronegative Kidney Allocation to Reduce PTLD Risk
This grant explores how adjusting immunosuppression and kidney donor matching by EBV status could lower the risk of EBV-related cancers in kidney transplant patients.
-
Understanding and preventing skin cancers in people who received organ transplants
This project studies why skin cancers are more common and more aggressive in kidney, liver, or other organ transplant recipients and how to better screen and manage them.
-
How immunosuppression and environmental factors affect skin cancer risk in organ transplant patients
This study is looking at why people who have had organ transplants are more likely to get certain skin cancers, like basal cell and squamous cell cancers, and it aims to find ways to better screen and manage these risks for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.